Molina’s 2026 “trough” is a rate-and-acuity lag story—painful near term, but with $11+ embedded EPS power once Medicaid rates reset, Florida CMS matures, and the portfolio pivots to duals.
The managed care sector is currently navigating a period of profound structural adjustment, characterized by a fundamental misalignment between state-reimbursed capitation rates and the surging utilization of healthcare services. Molina Healthcare, a cornerstone of the government-sponsored managed care market, provides a critical window into these dynamics. As an organization primarily serving Medicaid and Medicare beneficiaries alongside participants in state insurance marketplaces, its financial health is inextricably linked to the fiscal and legislative priorities of both state and federal governments.[1, 2, 3] The 2025 fiscal year represented a significant departure from historical performance trends, as the company grappled with "historic levels" of medical cost trend that effectively decoupled revenue growth from profitability.[1] This era of transition is defined by the 2026 "trough" year—a period of strategic retrenchment and operational recalibration intended to bridge the gap between current margin pressures and the realization of substantial embedded earnings.[4, 5]
To understand the current performance of Molina Healthcare, one must first analyze the broader environment of the managed care organization (MCO) industry. The conclusion of the COVID-19 Public Health Emergency triggered a massive "unwinding" process, during which states were required to redetermine the eligibility of all Medicaid enrollees.[6, 7] This process led to a nationwide decline in Medicaid enrollment of approximately $19.8\%$, dropping from a peak of $86.7$ million in March 2023 to $69.5$ million by October 2025.[6] For MCOs, this contraction was not merely a loss of volume but a significant shift in the risk pool’s "acuity profile".[3, 8] Healthier individuals tended to exit the rolls more rapidly, while those with chronic and complex medical needs remained, leading to a higher average cost per member that was not immediately reflected in the actuarial rates set by state agencies.[3, 9]
Molina Healthcare’s experience in this period is unique compared to its "Big Five" peers—Centene, CVS Health (Aetna), Elevance Health, and UnitedHealth Group.[6] While the industry saw sharp enrollment declines, Molina’s specialized focus on government programs allowed it to mitigate some of the most severe impacts of the unwinding.
| Company | Enrollment Change (Absolute) | Enrollment Change (%) | Medicaid as % of Total Base |
|---|---|---|---|
| Centene | $-3,804,000$ | $-23.3\%$ | $45.3\%$ |
| Elevance Health | $-3,389,000$ | $-28.5\%$ | $18.8\%$ |
| UnitedHealth Group | $-1,000,000$ | $-11.9\%$ | $14.8\%$ |
| CVS Health/Aetna | $-469,000$ | $-16.8\%$ | $8.7\%$ |
| Molina Healthcare | $-266,000$ | $-5.5\%$ | $83.2\%$ |
[6]
The data suggests that while larger, more diversified carriers experienced double-digit percentage losses in their Medicaid books, Molina Healthcare’s enrollment remained relatively stable with a decline of only $5.5\%$.[6] This stability, however, created its own challenges. By retaining a higher percentage of its membership through the redetermination process, Molina was more exposed to the "acuity shift" occurring across the remaining population.[3, 5] This exposure manifested in the second half of 2025, when medical costs surged across professional office visits, behavioral health, and high-cost pharmacy treatments.[4, 5]
The 2025 fiscal year was described by management as a "tale of two halves".[1, 5] In the first six months of the year, the company appeared to be successfully navigating the tail-end of the redetermination cycle, earning over $\$11.00$ per share and tracking toward its initial guidance.[1, 5] However, the third and fourth quarters saw a rapid deterioration in medical cost ratios across all business segments, exacerbated by non-recurring retroactive adjustments in the Medicaid line.[4, 10]
| Metric (In millions, except per-share data) | 2025 Actual | 2024 Actual | Year-over-Year Change |
|---|---|---|---|
| Premium Revenue | $\$43,052$ | $\$38,627$ | $+11.5\%$ |
| Premium Tax Revenue | $\$1,863$ | $\$1,486$ | $+25.4\%$ |
| Investment Income | $\$420$ | $\$452$ | $-7.1\%$ |
| Total Revenue | $\$45,426$ | $\$40,650$ | $+11.7\%$ |
| Medical Care Costs | $\$39,488$ | $\$34,428$ | $+14.7\%$ |
| GAAP Net Income | $\$472$ | $\$1,179$ | $-59.9\%$ |
| Adjusted Net Income | $\$ 584$ | $\$ 1,308$ | $-55.3\%$ |
| GAAP EPS – Diluted | $\$ 8.92$ | $\$ 20.42$ | $-56.3\%$ |
| Adjusted EPS – Diluted | $\$ 11.03$ | $\$ 22.65$ | $-51.3\%$ |
[4, 10, 11]
The decoupling of revenue and earnings is the most prominent feature of this period. While premium revenue grew by more than eleven percent—driven by organic expansion and the integration of acquisitions—medical care costs rose by nearly fifteen percent.[4, 12] This disparity caused the consolidated Medical Care Ratio (MCR) to rise from $89.1\%$ to $91.7\%$ for the full year.[4, 10]
The final three months of 2025 were particularly illustrative of the pressures facing the organization. The company reported a GAAP loss per diluted share of $\$3.15$ and an adjusted loss of $\$2.75$.[4]
| Segment MCR (Q4 2025) | Actual Ratio | Impacting Factors |
|---|---|---|
| Medicaid | $93.5\%$ | Retroactive rate cuts and risk corridor in California; high utilization. |
| Medicare | $97.5\%$ | Elevated LTSS and high-cost drug utilization; MAPD underperformance. |
| Marketplace | $99.0\%$ | Extreme utilization levels and prior-period provider claim settlements. |
| Consolidated | $94.6\%$ | Combined effect of retroactive items and broad utilization trends. |
[5]
Approximately $\$2.00$ per share of the fourth-quarter loss was attributable to "unfavorable and unexpected retroactive premium rate actions" by the State of California.[4, 5, 10] These adjustments involved both a reduction in current-period rates and a settlement of past-period risk corridors, creating a significant drag on the company’s capital position and earnings trajectory heading into 2026.[4, 5, 13]
As the organization’s primary revenue driver, accounting for over $81\%$ of total premiums, the Medicaid segment’s performance dictates the overall corporate outcome.[3, 8] The 2025 Medicaid MCR of $91.8\%$ was significantly higher than the organization’s long-term targets.[4] The underlying cause was a combination of "professional office visits, behavioral health services, and high-cost drugs".[5]
Management’s perspective on these costs is that they represent a temporary imbalance in the actuarial cycle. In the managed Medicaid model, states are required by federal law to set "actuarially sound" rates.[6] There is, however, a temporal lag between when an insurer experiences a cost spike and when the state actuarial process incorporates that data into new rates.[6] This lag is what management refers to when labeling 2026 as a "trough" year for margins.[4, 5, 10]
Despite the elevated MCR, the Medicaid segment continued to produce positive pre-tax margins. For the full year 2025, the Medicaid pre-tax margin was $2.8\%$.[9] When adjusting for the non-recurring California items in the fourth quarter, the underlying Medicaid pre-tax margin was approximately $2.0\%$.[5] This margin resilience, even at the bottom of the cycle, is a key metric cited by the CEO to support the durability of the platform.[4, 10]
The organization’s ability to maintain positive margins while peers like UnitedHealth Group signal "state funding shortfalls" suggests a highly disciplined cost structure.[6] Molina's General and Administrative (G&A) ratio for the Medicaid segment remained around $6.6\%$, reflecting ongoing operating leverage and discipline in the corporate cost base.[4, 5]
The Medicare segment, representing approximately $13\%$ of premium revenue, is undergoing a strategic transformation.[3, 14] The 2025 performance was marred by an MCR of $92.4\%$, which included a $97.5\%$ spike in the fourth quarter.[4, 5] This pressure was localized in two areas: high utilization among dual-eligible members for long-term services and supports (LTSS) and a failure of the traditional Medicare Advantage Part D (MAPD) product line to achieve sustainable margins.[5, 10]
In a significant move to protect future margins, Molina announced it would exit the traditional MAPD product for the 2027 plan year.[5, 10, 15] Management cited "strategic misalignment" and the "slow recovery" of the product’s margin profile as the primary reasons for this decision.[5, 10, 15]
| Product Type | Strategy for 2026/2027 | Rationale |
|---|---|---|
| D-SNP | Aggressive Expansion | High per-member revenue; strong care coordination synergy with Medicaid. |
| H-SNP | Selective Maintenance | Focus on institutionalized or chronic condition members. |
| Traditional MAPD | Complete Exit (2027) | High competition; low margin profile; misaligned with core Medicaid expertise. |
[5, 9, 10]
By exiting the MAPD space, the company is refocusing on its core competency: the "dual-eligible" population.[2, 3] These individuals represent a high-need, high-cost segment where Molina’s integrated Medicaid and Medicare care management models can drive the most significant clinical and financial value.[2, 3] The 2026 guidance already incorporates a $\$1.00$ per share drag from the underperformance of this exiting product line.[4, 5]
The Marketplace segment, which serves individuals on the ACA exchanges, has historically been a volatile but profitable "buffer" for the organization, smoothing the transition for members who lose Medicaid eligibility.[2, 16] In 2025, however, the segment became a major source of earnings pressure, with a full-year MCR of $90.6\%$ that included a $99\%$ ratio in the final quarter.[4, 5]
The response to this volatility in 2026 is a "conscious decision" to prioritize margin over enrollment volume.[5, 9] The organization is essentially cutting the segment in half through a combination of geographical exits and aggressive pricing.[5]
The target for this retrenched Marketplace segment is an MCR of $85.5\%$ in 2026.[4] If achieved, this would represent a nearly $500$ basis point improvement over 2025, contributing significantly to the stabilization of the corporate pre-tax margin.[4]
The guidance issued on February 5, 2026, was a seminal moment for the company’s valuation, as it reset investor expectations for the near term while highlighting the long-term potential of current contract wins.[4, 13]
Management’s guidance of "at least $\$5.00$" per adjusted share represents a low point in the organization’s earnings history, but it is "burdened" by specific, identifiable costs that are not expected to persist at these levels.[4, 10, 15]
| Headwind Factor | Estimated Impact (per share) | Nature of Headwind |
|---|---|---|
| Florida CMS Contract Ramp | $(\$1.50)$ | "New store" implementation costs; high initial utilization. |
| MAPD Product Underperformance | $(\$1.00)$ | Drag from the product line being exited for 2027. |
| Medicaid MCR Pressure | $(\$6.50)$ | The $140$ bps delta from previous MCR expectations. |
| Interest & Taxes | $(\$1.50)$ | Higher interest on recent note issuance and $30\%$ tax rate. |
| Underlying/Embedded Earnings | $11.00+$ | Potential earnings power at target margins. |
[5, 10, 15]
The $\$6.50$ per share impact from Medicaid MCR pressure is the most significant variable. Management’s assumption for 2026 is a Medicaid MCR of $92.9\%$.[4, 5] The "upside lever" identified by the CEO is that every $100$ basis points of improvement in this ratio from the current "trough" levels is worth nearly $\$5.00$ per share in earnings power.[5, 6]
A cornerstone of the 2026 outlook is the implementation of the new contract with the Florida Department of Health for the Children's Medical Services (CMS) program.[1, 5] This contract represents a "historic RFP win" and is projected to yield $\$6$ billion in annual premium revenue.[9, 13]
The financial dynamics of this contract are complex. In the short term (2026), it acts as a significant drag on earnings due to implementation and "new store" costs.[4, 5, 10] The $\$1.50$ per share drag reflects the upfront administrative costs and the typically higher medical utilization seen in new enrollees who may have had gaps in managed care coverage.[5, 10]
In the long term, however, the Florida CMS contract is the primary engine for the organization’s goal of returning to a mid-single-digit pre-tax margin.[1, 5] Management anticipates that as the contract matures—moving past the initial ramp-up in late 2026—it will contribute substantially to the "embedded earnings" which are currently valued at over $\$11.00$ per share.[1, 5, 10]
The current trough should be viewed in the context of an aggressive and highly successful growth strategy launched in 2019.[1] This strategy centers on three pillars: organic growth, inorganic expansion (M&A), and contract retention.[1, 18]
| Growth Metric | Financial Impact | Success Rate |
|---|---|---|
| New Contract RFPs | $\$20$ Billion in New Revenue | $80\%$ Win Rate |
| Contract Renewals | $\$14$ Billion in Retained Revenue | $90\%$ Win Rate |
| Bolt-on Acquisitions | $\$9$ Billion in Revenue | $N/A$ |
| Total Secured Revenue | $\$43$ Billion | N/A |
[1, 5]
The high win rates on renewals ($90\%$) and new contracts ($80\%$) suggest that state regulators value Molina’s "pure-play" expertise.[1, 3, 5] Recent specific wins include:
* Florida CMS: $\$6$ billion annually.[9, 13]
* Michigan & Virginia: Core Medicaid renewals secured, although Virginia saw some contract loss that will be a headwind in 2026.[2, 5]
* Nebraska: New market entry through procurement.[2]
* Massachusetts & Ohio: Targeted Medicare/D-SNP contract wins scheduled for 2026 commencement.[18]
This track record of winning and retaining business is the primary justification for management’s optimistic "future earnings trajectory".[1] The organization has effectively built a $\$42$ billion to $\$45$ billion revenue base that, if returned to historical $4-5\%$ pre-tax margins, would generate earnings vastly superior to the current trough guidance.[5, 10, 14]
The healthcare landscape for the remainder of the decade will be defined by the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025.[19, 20, 21] This massive budget reconciliation package contains the most significant changes to Medicaid and ACA financing in recent history, with the specific intent of reducing federal spending and increasing "program integrity".[19, 20]
The OBBBA’s impacts on the managed care sector are projected to be deep and lasting, beginning in earnest in the 2026 and 2027 fiscal years.[19, 22]
Work Requirements for Expansion Populations:
Starting in January 2027, non-disabled adults covered under the ACA Medicaid expansion must demonstrate employment or participation in work-related activities to maintain coverage.[19, 20, 22] While some exemptions exist for caregivers and the disabled, research by the Urban Institute projects coverage losses of $3.0$ to $7.0$ million expansion enrollees because of these requirements alone.[22]
Increased Redetermination Frequency:
The law mandates that states check the eligibility of Medicaid expansion enrollees every six months, rather than the previous annual standard.[19, 21] This increase in administrative frequency is expected to cause an additional $2.0$ to $3.1$ million enrollees to lose coverage due to "procedural churn"—the loss of coverage by eligible individuals who fail to navigate the increased paperwork requirements.[21, 22]
FMAP Incentive Expiration:
The American Rescue Plan’s incentive for states to expand Medicaid (a two-year, five-percentage point bump to the Federal Medical Assistance Percentage) will expire in 2026.[23] This is expected to halt further expansion in the remaining ten non-expansion states, limiting the "total addressable market" for new Medicaid MCO growth.[23]
The Congressional Budget Office (CBO) and independent researchers have developed stark projections for the Medicaid program under the OBBBA.
| Source | Projected Enrollment Loss | Projected Budget Reduction |
|---|---|---|
| CBO / Joint Committee | $11.4$ Million fewer by 2034 | $N/A$ |
| RAND Corporation | $7.6$ Million fewer by 2034 | $\$665$ Billion (State) / $\$714$ Billion (Fed) |
| Urban Institute | $4.9$ to $10.1$ Million (Expansion) | $37\%$ to $68\%$ reduction in state expansion books. |
[6, 20, 21, 22]
For Molina Healthcare, which has an expansion book of approximately $1.3$ million members generating $\$8$ billion in annual premium, these changes represent a "multi-year trajectory of premium growth" potentially turning into a period of contraction.[5, 24] However, management has noted that the "redetermination effects" from the previous 2023-2024 cycle have already removed many "low/no-utilization" members, which may make the remaining pool more resilient to administrative churn than the general population.[5]
Molina Healthcare’s primary competitive advantage is its "pure-play" status in the government-sponsored managed care market.[3, 25] Unlike diversified competitors such as UnitedHealth Group (which has massive employer-sponsored and Optum service divisions) or CVS Health (which has retail and PBM assets), Molina’s focus is singular.[1, 3]
The "Big Five" publicly held companies control roughly $50\%$ of the Medicaid managed care market.[6]
| Company | Medicaid Subsidiary Count | Subsidiary Presence (States) | Total Medicaid Enrollment |
|---|---|---|---|
| Centene | $30$ | $29$ | $12,518,000$ |
| Elevance Health | $22$ | $21$ | $8,500,000$ |
| UnitedHealth Group | $30$ | $27$ | $7,380,000$ |
| Molina Healthcare | $20$ | $19$ | $4,568,000$ |
| CVS Health/Aetna | $13$ | $12$ | $2,325,000$ |
[6]
The organization’s "cultural competence" and dedicated local provider networks are frequently cited as the reason for its $80\%$ win rate on new contracts.[1, 3, 25] While larger players may have more total capital, Molina’s leaner administrative structure—often maintaining a G&A ratio near $6.5\%$ compared to industry averages closer to $8-10\%$/—allows it to bid more aggressively on state contracts while preserving a pathway to profitability.[4, 14, 16]
Furthermore, the organization’s high Medicare Star Ratings and long-standing regulatory ties create a barrier to entry for smaller, regional plans.[16] The "Molina Way" of technology integration also allows the company to rapidly scale newly acquired plans, converting them from loss-making to profitable within an eighteen-month window—a capability that is essential in an environment where state budgets are increasingly "tenuous".[7, 16]
Managing through a trough year requires a robust balance sheet and access to capital markets. Molina Healthcare enters 2026 with a stable financial profile, albeit one that has been stressed by the second-half 2025 performance.[2, 4, 25]
| Metric | Value | Significance |
|---|---|---|
| RBC Ratio (Aggregate) | $305\%$ | $50\%$ above state regulatory minimums. |
| Debt-to-Capitalization | $\approx 49\%$ | Reflects $\$850$M in senior notes issued Nov 2025. |
| Debt-to-EBITDA | $3.7x$ | Trailing 12-month basis; manageable for an MCO. |
| Parent Co. Cash | $\$223$ Million | Liquidity for parent-level operations and debt service. |
| Days in Claims Payable | $47$ | Consistent with historical actuarial practices. |
[5, 9, 26]
The operating cash flow for 2025 was an outflow of $\$535$ million, a significant deviation from the $\$644$ million inflow in 2024.[4, 10] This decrease was primarily driven by Medicaid risk corridor settlement activity in California and the timing of tax payments.[4, 10] For the organization to return to a neutral or positive cash flow position in 2026, it will need to see a stabilization of the Medicaid MCR and the successful commencement of the Florida contract.[4, 5, 9]
The parent company cash balance of $\$223$ million was bolstered by $\$337$ million in dividends from its operating subsidiaries in the fourth quarter, highlighting the ability of the health plans to upstream cash even during periods of earnings pressure.[5] This liquidity is critical for maintaining an "investment-grade posture" and funding the M&A pipeline, which remains active with over $\$50$ billion in potential opportunities.[2, 9]
The stock market’s reaction to the 2025 earnings results and the 2026 guidance has been negative in the medium term, but technical indicators suggest that a bottom may be forming as the "acuity shift" is priced into the valuation.[3, 17]
As of mid-April 2026, the stock (NYSE: MOH) is trading around $\$149.00$.[17, 27]
| Indicator | Value / Direction | Interpretation |
|---|---|---|
| 52-Week Range | $\$121.06 - \$333.22$ | Stock is trading in the lower part of its range. |
| 200-Day SMA | $\$167.22$ (Declining) | Long-term trend remains negative. |
| 50-Day SMA | $\$143.24$ (Declining) | Current price is above the declining 50-day average. |
| 20-Day SMA | $\$141.73$ (Rising) | Short-term momentum is turning positive. |
| MACD (12,26,9) | $1.6$ (Positive) | Suggests a positive trend is developing. |
| RSI (14) | $52.95$ | Neutral; not yet in overbought territory. |
| Stochastics | $82.19$ | Slightly overbought in the very short term. |
[17, 27, 28]
The technical rating of $2$ out of $10$ from ChartMill reflects a "below average" performance relative to the S&P 500, which has been hitting new highs while the managed care sector has languished.[17] However, the setup rating of $8$ out of $10$ indicates that the stock is currently in a consolidation phase with reduced volatility, which often precedes a "breakout" if fundamental news—such as Q1 2026 earnings—surprises to the upside.[17]
Analysts' consensus price targets are clustered around the $\$146$ to $\$150$ range, representing a "Hold" sentiment.[29, 30] The low price target of $\$124$ and the high of $\$180$ reflect the deep uncertainty regarding the speed of Medicaid margin restoration.[30]
A critical factor in the organization’s recovery story is the stability and alignment of its leadership team. Joseph Zubretsky has led the company through its growth strategy since 2019 and maintains a substantial equity stake.[1, 31]
| Component | 2025 Estimated Value | Change from 2024 |
|---|---|---|
| Total Estimated Pay | $\$18,340,783$ | $-19.65\%$ |
| Restricted Stock Grant | $66,417$ Shares | Multi-year vesting (2027-2029). |
| Direct Ownership | $99,015$ Shares | Following March 2026 vesting activity. |
| Indirect Ownership | $257,715$ Shares | Held through Revocable Trust. |
[31, 32, 33]
The decrease in CEO compensation reflects the "disappointing financial performance" of the 2025 fiscal year, as incentive-based payouts were likely reduced.[1, 33] The structure of the restricted stock grants, which vest in one-third increments over three years, ensures that the executive team is focused on the long-term "future earnings trajectory" rather than short-term stock price movements during the 2026 trough.[31]
Board members are similarly aligned, with an annual equity grant of $\$220,000$ paid in quarterly installments.[26] This consistency in equity grants, even as the stock price declined in late 2025, means that directors and executives have been "averaging down" their cost basis alongside shareholders, further tightening the alignment between the board and the investor base.[26]
The organization’s future is a "story of mean reversion".[3] If the company can navigate the immediate challenges of the OBBBA and the Florida CMS ramp, the potential for earnings growth is significant.
| Fiscal Year | Forecasted Revenue | Forecasted EPS | Projected Growth Rate |
|---|---|---|---|
| 2025 (A) | $\$45.43$ Billion | $\$11.03$ (Adj) | $N/A$ |
| 2026 (E) | $\$42.20$ Billion | $\$ 5.03$ (Adj) | $-54\%$ (The Trough) |
| 2027 (E) | $\$46.90$ Billion | $\$ 8.31$ (Adj) | $+65\%$ (Recovery) |
| 2028 (E) | $\$49.10$ Billion | $\$13.31$ (Adj) | $+60\%$ (Embedded Realization) |
[30, 34, 35]
By 2032, long-term forecasts suggest revenue could reach nearly $\$62$ billion, assuming a $2.67\%$ to $4.1\%$ annual growth rate.[30, 36] The key to this growth is not just enrollment, but the expansion into higher-margin dual-eligible plans and the strategic use of AI and predictive analytics to identify high-risk patients before they require expensive emergency room visits.[3, 16, 37]
The performance of Molina Healthcare in 2025 and 2026 represents a seminal correction in the managed care industry. The convergence of post-pandemic redeterminations, the historic cost trends of 2025, and the legislative constraints of the OBBBA have created a "perfect storm" that has temporarily depressed the organization’s earnings power. However, a deeper analysis of the company's fundamentals reveals a highly resilient franchise.
The core of the "Molina Story" in 2026 is the realization of embedded earnings. With $\$11.00$ per share in potential earnings power already secured through current contracts and a disciplined exit from underperforming products like MAPD, the organization is effectively "coiling" for a strong recovery in 2027. The $\$6$ billion Florida CMS contract, while a headwind in the short term, will eventually serve as a massive tailwind to both revenue and margins.
For professional peers and industry analysts, the key monitorable items over the next four quarters will be the speed at which state Medicaid agencies provide rate relief and the organization's success in managing the OBBBA-mandated six-month redetermination cycles. If Molina can maintain its historical $90\%$ renewal success rate and continue to leverage its lean $6.5\%$ G&A structure, the current trough will likely be viewed in hindsight as a rare opportunity to value a specialized industry leader at a substantial discount to its long-term earnings potential. The organization’s durable operating platform, backed by a disciplined management team and a massive contract pipeline, remains fundamentally sound, positioning it as a primary beneficiary of the eventual equilibrium between medical trend and actuarial rates.
View Molina Healthcare, Inc. (MOH) stock page
Loading the interactive version of this report…